NOVATIO ACCELERATES THE COMMERCIALIZATION OF HIGH-POTENTIAL, HIGH-IMPACT LIFE SCIENCE INNOVATIONS. Based in Toronto, Boston and Hong Kong, we focus on the global development of innovations arising from Canada, China, South Korea, and other markets that we believe represent a significant source of opportunities for outsized value creation. We target early stage innovation on the cusp of preclinical proof-of-concept or validation. We will provide seed funding and work actively with inventors, entrepreneurs, and institutions to devise and implement development and commercialization strategies, assemble management teams, and secure additional capital. We aim to leverage our collective experience and global industry network to achieve early exits that generate attractive, risk-mitigated financial returns. WE HELP BRING INNOVATION TO MARKET BY PROVIDING SEED CAPITAL AND MANAGEMENT SERVICES. Novatio’s primary focus is to identify and invest in innovative technologies that will make a real impact on the way diseases are diagnosed and treated. We will invest in these innovations at an early stage and, when necessary, build and manage companies to enable their development. For more mature opportunities, we will add value by using our fundraising, monetization, business development and licensing expertise to help secure investments and partnerships that will fund and expedite eventual commercialisation.